Psyence BioMed Sets January 20, 2026 Start Date for 1-for-6.25 Reverse Stock Split
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Psyence Biomedical ( (PBM) ) is now available.
On January 14, 2026, Psyence BioMed announced that its previously approved 1-for-6.25 reverse stock split of common shares will take effect with post-consolidated trading expected to begin on January 20, 2026 on the Nasdaq Capital Market under the existing PBM symbol but with a new CUSIP number. The move, following an earlier 1-for-7.97 share consolidation implemented in May 2025 and authorized by shareholders at a special meeting on April 16, 2025, will reduce the company’s outstanding common shares from 6,388,604 to approximately 1,022,177, proportionally adjust warrants and other equity instruments, and uniformly affect all shareholders aside from minor rounding for fractional shares, potentially influencing Psyence BioMed’s share price dynamics and its efforts to maintain compliance with Nasdaq’s listing requirements while clarifying the mechanics for both registered and beneficial holders through its transfer agent, Continental Stock Transfer & Trust Company.
More about Psyence Biomedical
Psyence Biomedical Ltd. (Psyence BioMed) is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. Listed on Nasdaq under the ticker PBM, it focuses on developing nature-derived (non-synthetic) psilocybin- and ibogaine-based medicines aimed at addressing unmet mental health needs through an evidence-based approach and the pursuit of safe, effective, regulator-approved treatments for a broad range of mental health disorders.
Average Trading Volume: 1,374,149
Technical Sentiment Signal: Sell
Current Market Cap: $1.49M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.
